Navigation Links
Volcano Corporation Announces $200 Million Share Repurchase Authorization
Date:12/2/2013

nced by the Company; the Company's decisions with respect to its capital allocation strategy; the pace and extent of market adoption of the Company's products and technologies; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; unexpected manufacturing issues; growth strategies; timing and achievement of product development milestones; outcome of ongoing litigation; the impact and benefits of market development; product introductions, including delays; unexpected new data, safety and technical issues; market conditions affecting the Company's products and technologies; and other risks inherent to medical device development and commercialization. These and additional risks and uncertainties are more fully described in Volcano's filings made with the Securities and Exchange Commission, including our  recent quarterly report on Form 10-Q. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made. Volcano undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

 


'/>"/>
SOURCE Volcano Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Volcano Corporation Presentation At JMP Securities Conference To Be Webcast
2. Volcano to Highlight its Leadership in Precision Guided Therapy at EuroPCR 2012
3. Volcano Corporation Presentation At Jefferies Conference To Be Webcast
4. Volcano Corporation Presentation at Wells Fargo Conference to be Webcast
5. Volcano Corporation Schedules Second Quarter Conference Call, Webcast
6. Volcano Corporation Reports 13 Percent Growth In Second Quarter Revenues; FFR Disposable Revenues Increase 38 Percent
7. Volcano Corporation Presentation At Canaccord Genuity Conference To Be Webcast
8. FAME 2 Published in the New England Journal of Medicine, Volcano participates in the $84M NIH-Sponsored ISCHEMIA Trial
9. Volcano Corporation Presentation At Stifel Nicolaus Conference To Be Webcast
10. Volcano Announces Previous St. Jude Medical Products Infringe Volcano Patent and Jury Verdicts in Patent Trials with St. Jude Medical
11. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DUBLIN , Jan. 15, 2014  Research and Markets ... "Dental Consumables Market - Global Industry Analysis, Size, ... report to their offering. (Logo: ... products which are used on patients in order to ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... DIEGO, Aug. 12, 2011 / PRNewswire/ -- Halozyme ... company developing and commercializing products targeting the extracellular ... at the Wedbush 2011 Life Sciences Conference in New ... at 9:10 a.m. EDT (6:10 a.m. PDT). To listen ...
... WOODLANDS, Texas, Aug. 11, 2011 Lexicon Pharmaceuticals, ... company focused on discovering breakthrough treatments for human disease, ... , Lexicon,s president and chief executive officer, will present ... on Tuesday, August 16, 2011 at 1:15 p.m. Eastern ...
Cached Medicine Technology:Halozyme Therapeutics to Present at the Wedbush 2011 Global Healthcare Conference on August 17 2Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference 2
(Date:7/9/2014)... stromal support cells and immune cells and the ... the development of diseases could open new therapeutic ... the conclusion of a review article by scientists from ... Nature . , Prof. Peter Carmeliet: "Consider the review ... cancer cells has been examined in minute detail for ...
(Date:7/9/2014)... feelings are personal and subjective, the human brain ... represents emotions across different senses, situations and even ... neuroscientist Adam Anderson. , "We discovered that fine-grained ... an area of the brain associated with emotional ... an individual,s subjective feeling," says Anderson, associate professor ...
(Date:7/9/2014)... for more than watching World Cup highlights, Brian Williams ... landing in unfortunate positions on railings. A University of ... Online Journal shows that YouTube also allows researchers, ... public on topics of skin cancer and prevention. , ... the future of how we communicate around the world," ...
(Date:7/9/2014)... labels handed out by pharmacists may be misread ... according to new research by the University of ... Blind)., The study, published recently in the ... prescription medications dispensed by pharmacies do not consistently ... simply following recommended guidelines for font size, use ...
(Date:7/9/2014)... microbiologists from the Keck School of Medicine of ... that mice lacking a specific component of the ... potentially fatal complication of infection. The discovery suggests ... reduce inflammation in human autoimmune and hyper-inflammatory diseases ... , The study was published online on June ...
Breaking Medicine News(10 mins):Health News:Wake-up call for more research into cell metabolism 2Health News:Study cracks how the brain processes emotions 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... U.S. Department of Energy,s (DOE) Brookhaven National Laboratory have ... design of a "medical synchrotron" capable of delivering precision ... damage to surrounding healthy tissue. The new device would ... systems, potentially increasing the availability and benefits of this ...
... There is a new,Internet service available that changes the ... stay informed, it allows,long-term care providers to give them regular ... text message without families having,to call, no matter where they ... to do and too little time. It,s a common problem ...
... and digital radiography highlighted at RSNA 2008 , ... Siemens Healthcare ( ... from fluoroscopy and digital radiography to interventional radiology, at ... Radiological Society of North America (RSNA) from November 30 ...
... Pharmaceuticals, Inc. (Nasdaq: IDIX ) announced today that ... Conference on Wednesday, December 3, 2008 at 4:30p.m. ET at ... , The live and archived ... of Events" in the Idenix Investor Center at www.idenix.com ...
... Inc.,(Nasdaq: CEPH ) and ImmuPharma PLC (LSE: ... have signed an Option Agreement,providing Cephalon with an option ... Lupuzor(TM) for the treatment of Systemic Lupus,Erythematosus. ImmuPharma ... in patients in Europe and Latin America. , ...
... 25 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... monoclonal antibodies for the treatment of serious ... U.S. Patent and Trademark,Office has issued U.S. ... covering anti-viral applications of antibodies that directly ...
Cached Medicine News:Health News:Physicists receive patent for improved cancer therapy device 2Health News:Physicists receive patent for improved cancer therapy device 3Health News:New Internet Service Delivers Relief to Families of Those in Long-Term Care 2Health News:Siemens Demonstrates Flexibility, Enhanced Workflow and Imaging Excellence 2Health News:Siemens Demonstrates Flexibility, Enhanced Workflow and Imaging Excellence 3Health News:Siemens Demonstrates Flexibility, Enhanced Workflow and Imaging Excellence 4Health News:Siemens Demonstrates Flexibility, Enhanced Workflow and Imaging Excellence 5Health News:Siemens Demonstrates Flexibility, Enhanced Workflow and Imaging Excellence 6Health News:Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication 2Health News:Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication 3Health News:Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication 4Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies 2Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies 3Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: